Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • OtherActive, not recruiting Location: USA

    Viral pathogenisis of early cystic fibrosis lung disease , protocol number 1R01HL116211-01 NCT01973192

    Study will test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.

    • Age:

      2-4 months

    • Mutation(s):

      Hetrozygous

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-1P-15

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectivness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      3

    • Length of Participation:

      35 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of Ataluren in people with CF who have a nonsense mutation and are not taking aminoglycosides. , protocol number PTC124-GD-021-CF

    This study is taking place at multiple care centers across the U.S. It looked at the effectiveness and safety of the oral drug ataluren in people with CF who have a nonsense mutation of cystic fibrosis. This study used a placebo control.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      10

    • Length of Participation:

      56 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells. , protocol number ProQR PQ-010-002

    This study is taking place at multiple care centers across the U.S. It will explore whether the drug QR-010 administered through nasal spray can increase the movement of salt in and out of the nasal cells.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor. , protocol number Nivalis N91115-2CF1-05

    This study is taking place at multiple care centers across the U.S. It will test the safety and effectiveness of a new type of CFTR modulator drug called N91115 in adults with cystic fibrosis who are currently taking lumacaftor/ivacaftor. It will also look at how the body processes the drug.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 85%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SNO4: Study of N91115 in people with cystic fibrosis ages 18 and older with two copies of F508del-CFTR mutation. , protocol number Nivalis N91115-2CF-03

    This study is taking place at multiple care centers across the U.S. It will look at the safety of the drug N91115 as well as how the body processes the drug, in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      6 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SNO1: Study of N6022 in people with cystic fibrosis , protocol number Nivalis N30 N6022-1CF1-04

    This study tested the safety, tolerability of N6022 and its effects on CFTR biomarkers in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      10

    • Length of Participation:

      6 weeks

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enterel tube feedings , protocol number Alcresta 0000497

    This study took place at multiple care centres across the US. It looked at the safety and effectiveness of Relizorb, a new tube feeding in-line digestive enzyme cartridge. This cartridge is used with tube feedings to deliver digestive enzymes.

    • Age:

      4 Years to 82 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 100%

    • Number of Visits:

      4

    • Length of Participation:

      27 days

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Arikace for Nontuberculous Mycobacteria (NTM) , protocol number Insmed 112

    The purpose of this study was to determine whether Arikace is effective in treating recalcitrant nontuberculous mycobacterial lung disease. The safety and tolerability of Arikace in this patient population was also assessed.

    • Age:

      12 Years to 75 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      0

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Displaying results 61-70 (of 130)
     |<  <  3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12  >  >|